CYP3A4, namely hepatic cytochrome P450 subfamily III A polypeptide 4, contributes to the metabolism of 45–60% of all drugs used in the clinical setting; its decreased expression and function were reported to be related to non−alcoholic fatty liver disease [65]. Here, CYP3A4 is linked to fatty liver disease.